3 professionals
Interest of a dermo-cosmetic product in the prevention of eyelids dermatitis relapses
Interest of a dermo-cosmetic product in the prevention of eyelids dermatitis relapses
Sandrine Bergera-Virassamynaïk1, Marlène Chavagnac-Bonneville1,2, Christelle Graizeau1,2 and Michèle Sayag1
1NAOS Group, Research and Development Department, Aix-en-Provence, France
2NAOS Institute of Life Science, Aix-en-Provence, France
Related topics
Atopic dermatitis can affect eyelids in 25 to 45% of cases, and even with the allergenic or irritant agent removal, careful and repeated cleansing, and topical corticosteroids (TC) treatment, relapses are common.
The aim was to evaluate the preventive effect on relapses, the impact on quality of life, the efficacy and the safety of a specific dermo-cosmetic product on eyelids of atopic patients.
In a randomized comparative study, 66 atopic subjects (mean age 46 years) under TC treatment prescribed for palpebral dermatitis flare-up were divided in two groups: the control group using their usual hygiene product, and the product group using the dermo-cosmetic product twice daily for 168 days. During the study, the relapse number was collected, and the quality of life (DLQI : Dermatology Life Quality Index), the efficacy and the safety of the product were assessed.
After 168 days, a mean of 0.67 relapses were observed vs. 5.09 in the control group (p<0.001), corresponding to a decrease of 85% in the product group. Moreover, 76% of the subjects in the product group presented no relapse, whereas all subject presented at least one relapse in the control group. The mean time of the relapse delay was 29 days vs. 32 days in the control group. A significant decrease of DLQI scores between the two groups indicated that the product had a positive impact on the quality of life in atopic patients. Furthermore, 91% to 100% of the subjects agreed that the product left the skin comfortable and repaired, soothed irritation, itching, and dryness, and prevented irritation. The product was very well-tolerated by all subjects.
By its preventing effect, this dermo-cosmetic product offers a real interest in management of atopic dermatitis eyelids and relieves the chronic disease burden of atopic subjects.
Sandrine Bergera-Virassamynaïk1, Marlène Chavagnac-Bonneville1,2, Christelle Graizeau1,2 and Michèle Sayag1
1NAOS Group, Research and Development Department, Aix-en-Provence, France
2NAOS Institute of Life Science, Aix-en-Provence, France
Bergera-Virassamynaïk S. and Sayag M.
NAOS, Research and Development Department, Lyon, France
Create easily your professional account
I create my accountGet access to exclusive dermatological services to increase your professionnal knowledge: +500 pathology visuals, clinical cases, expert videos
Benefit from valuable features: audio listening, materials to be shared with your patients
Stay informed about the upcoming events and webinars, latest scientific publications and product innovations